The BioPharm Brief: CAR-T, RNAi, and Inhaled ASOs

Sep 08, 09:00 PM
Headliner
Share
Subscribe

BrainChild Bio, Moonwalk Biosciences, and Aptar Pharma are advancing new approaches to CAR-T therapy, RNAi for obesity, and inhaled antisense oligonucleotide delivery.

Share
Subscribe
Next
The BioPharm Brief: Setbacks, Submissions, and a $1.3B Deal
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief